Metformin Reduces Repeat Mild Concussive Injury Pathophysiology

eNeuro. 2022 Jan 13;9(1):ENEURO.0421-21.2021. doi: 10.1523/ENEURO.0421-21.2021. Print 2022 Jan-Feb.

Abstract

Mild traumatic brain injury (mTBI) can initiate complex pathophysiological changes in the brain. Numerous cellular and molecular mechanisms underlying these pathologic changes are altered after injury, including those involved in energy utilization, excitotoxicity, ionic disturbances, and inflammation. It is thought that targeting multiple mechanisms may be necessary to produce meaningful reductions in brain pathology and to improve outcome. Previous studies have reported that the anti-diabetic drug metformin can also affect inflammatory, cell survival, and metabolic outcomes, possibly by acting on multiple targets and/or pathways. We therefore questioned whether metformin treatment can reduce pathology after repeat mild closed head injury (rmCHI) in male C57Bl/6 mice. We found that metformin, administered acutely after each head impact, resulted in markedly reduced white matter damage, astrogliosis, loss of hippocampal parvalbumin neurons, and improved mitochondrial function. In addition, both motor and cognitive functions were significantly improved when tested after discontinuation of the treatment. These studies suggest that metformin may be beneficial as a treatment for repeat concussion.

Keywords: axonal injury; cognitive dysfunction; mild traumatic brain injury; oxygen consumption rate; repeat concussion; tissue respiration.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain
  • Brain Concussion* / drug therapy
  • Disease Models, Animal
  • Head Injuries, Closed*
  • Male
  • Metformin* / pharmacology
  • Mice
  • Mice, Inbred C57BL

Substances

  • Metformin